



*DM*

PATENT  
Atty. Docket No. PP-18892.003

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in a box addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 9/8/05 By: *Jeanne Lupton*  
Date Jeanne Lupton

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Applicants: Vajdy, Michael, et al.  
Application No. 10,501,606  
371(c) Date: April 11, 2005  
Group Art Unit: 1648  
Confirmation No.: 9598  
Examiner: Stucker, J.J.  
For: HIV VACCINE AND METHOD OF USE

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97(b)(3)**

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The citations listed on the enclosed Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Copies of these references are enclosed herewith. The Examiner is requested to make these citations of official record in the present applications.


The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and, therefore, no certification under 37 C.F.R. §1.97(e) or fee

under 37 C.F.R. §1.17(p) is required.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By:   
Helen Lee  
Reg. No. 39,270

Date: September 8, 2005

CHIRON CORPORATION  
Intellectual Property Dept.  
4560 Horton Street  
Emeryville, CA 94608-2916  
Telephone: (510) 923-2192  
Facsimile: (510) 655-3542

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT**  
 UNDER 37 CFR §1.56, §1.97, AND §1.98

PTO-1449 FORM (MODIFIED)

SHEET 1 OF 1



ATTORNEY DOCKET NO. PP18892.003	SERIAL NO. 10/501,606
APPLICANTS: Michael Vajdy et al.	EXAMINER: Stucker, J.J.
371(c) DATE: April 11, 2005	
CONFIRMATION NO. 9598	GROUP ART UNIT: 1648

**U.S. PATENT DOCUMENTS**

Ex'r Initial	Ref. No.	Document No.	Date	Name	Class	Subclass	Filed
	A1						
	A2						
	A3						

**FOREIGN PATENT DOCUMENTS**

Ex'r Initial	Ref. No.	Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	B1	WO 01/37869 A1	31 May 2001	PCT				
	B2							
	B3							

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ex'r Initial	Ref. No.	Description
	C1	Pizza, M., et al., "Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants," <i>Vaccine</i> , 19:2534-2541 (2001).
	C2	Pizza, M., et al., "LTK63 and LTR72, two mucosal adjuvants ready for clinical trials," <i>Int. J. Med. Microbiol.</i> , 290:455-461 (2000).
	C3	Neidleman, J.A., et al., "Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55," <i>Immunology</i> 101:154-160 (2000).
	C4	Partidos, C.D., et al., "The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide," <i>Immunology</i> 89:483-487 (1996).
	C5	Cohen, J., "AIDS Vaccines Show Promise After Years of Frustration," <i>Science</i> 291:1686-1688 (2001).
	C6	Spalding, B.J., "In Hot Pursuit of an HIV Vaccine," <i>Bio/Technology</i> 10:24-29 (1992).

EXAMINER'S SIGNATURE	DATE CONSIDERED
----------------------	-----------------

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609.  
 Line through citation if not in conformance and not considered.  
 Include copy of this form in next communication to applicant.

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).